PSP Research LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

Posted by Brian Himes on May 20th, 2026

PSP Research LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,026 shares of the biopharmaceutical company’s stock, valued at approximately $540,000. Halozyme Therapeutics makes up 0.5% of PSP Research LLC’s investment portfolio, making the stock its 23rd biggest position.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. Clark Capital Management Group Inc. grew its position in shares of Halozyme Therapeutics by 14.4% in the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after buying an additional 25,582 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Halozyme Therapeutics by 46.0% in the 3rd quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after buying an additional 46,850 shares during the last quarter. Allworth Financial LP grew its position in shares of Halozyme Therapeutics by 322.5% in the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after buying an additional 30,331 shares during the last quarter. ING Groep NV purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $6,652,000. Finally, Element Squared LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $1,193,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 1.9%

HALO stock opened at $68.73 on Wednesday. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22. The stock has a market capitalization of $8.15 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a fifty day moving average of $65.67 and a 200-day moving average of $68.70.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter last year, the business earned $1.11 EPS. The business’s revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the completion of the sale, the director owned 38,498 shares in the company, valued at approximately $2,443,853.04. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $53,122,698.20. This trade represents a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 120,482 shares of company stock worth $8,200,842. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on HALO shares. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Read Our Latest Stock Analysis on HALO

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.